Elan's Frova approved in the U.S.

The FDA approved ELN's Frova frovatriptan 2.5 mg tablets for the acute treatment of migraine attacks with or without aura in adults. Frova is a 5-HT receptor agonist. ELN received exclusive North American sales and distribution rights to Frova from Vernalis (LSE:VER). The partners received an approvable letter for Frova in May 2000, with final approval dependent on FDA review of data from an ongoing long-term preclinical safety study requested by the agency. ...